WallStreetZenWallStreetZen

NASDAQ: AVRO
Avrobio Inc Stock

$1.47-0.01 (-0.68%)
Updated May 29, 2024
AVRO Price
$1.47
Fair Value Price
$2.19
Market Cap
$65.99M
52 Week Low
$0.88
52 Week High
$1.65
P/E
2.1x
P/B
0.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$30.31M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$50M
Beta
1.19
Next Earnings
Jun 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AVRO Overview

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AVRO ($1.47) is undervalued by 32.75% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AVRO ($1.47) is significantly undervalued by 32.75% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AVRO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more AVRO due diligence checks available for Premium users.

Be the first to know about important AVRO news, forecast changes, insider trades & much more!

AVRO News

Valuation

AVRO fair value

Fair Value of AVRO stock based on Discounted Cash Flow (DCF)
Price
$1.47
Fair Value
$2.19
Undervalued by
32.75%
AVRO ($1.47) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVRO ($1.47) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

AVRO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
2.1x
Industry
15.85x
Market
31x
AVRO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AVRO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

AVRO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.74x
Industry
5.94x
AVRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AVRO's financial health

Profit margin

Revenue
$0.0
Net Income
-$6.8M
Profit Margin
0%
AVRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$92.3M
Liabilities
$3.5M
Debt to equity
0.04
AVRO's short-term assets ($91.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVRO's short-term assets ($91.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVRO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.6M
Investing
$0.0
Financing
$30.0k
AVRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AVRO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AVRO$65.99M-0.68%2.10x0.74x
MNOV$66.21M+2.20%-7.94x1.11x
INTS$66.37M-2.81%-2.35x6.83x
ANVS$67.03M-9.77%-1.17x-19.98x
CLGN$64.91M-4.76%-8.59x2.66x

Avrobio Stock FAQ

What is Avrobio's quote symbol?

(NASDAQ: AVRO) Avrobio trades on the NASDAQ under the ticker symbol AVRO. Avrobio stock quotes can also be displayed as NASDAQ: AVRO.

If you're new to stock investing, here's how to buy Avrobio stock.

What is the 52 week high and low for Avrobio (NASDAQ: AVRO)?

(NASDAQ: AVRO) Avrobio's 52-week high was $1.65, and its 52-week low was $0.88. It is currently -10.91% from its 52-week high and 67.05% from its 52-week low.

How much is Avrobio stock worth today?

(NASDAQ: AVRO) Avrobio currently has 44,893,750 outstanding shares. With Avrobio stock trading at $1.47 per share, the total value of Avrobio stock (market capitalization) is $65.99M.

Avrobio stock was originally listed at a price of $31.20 in Jun 21, 2018. If you had invested in Avrobio stock at $31.20, your return over the last 5 years would have been -95.29%, for an annualized return of -45.72% (not including any dividends or dividend reinvestments).

How much is Avrobio's stock price per share?

(NASDAQ: AVRO) Avrobio stock price per share is $1.47 today (as of May 29, 2024).

What is Avrobio's Market Cap?

(NASDAQ: AVRO) Avrobio's market cap is $65.99M, as of May 30, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Avrobio's market cap is calculated by multiplying AVRO's current stock price of $1.47 by AVRO's total outstanding shares of 44,893,750.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.